Isabel Bover

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rafael Rosell, Enric Carcereny, Radj Gervais et al. · The Lancet Oncology · 2012 · 5.5K citations · Full text

Medicine, Oncology, Pharmacology +12

Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

Rafael Rosell, Teresa Morán, Cristina Queralt et al. · New England Journal of Medicine · 2009 · 2.4K citations · Full text

Medicine, Genetics, Oncology +11

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

Tudor–Eliade Ciuleanu, Thomas Brodowicz, Christoph Zielinski et al. · The Lancet · 2009 · 1.1K citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Tumor Markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in Patients with Non-Small Cell Lung Cancer as an Aid in Histological Diagnosis and Prognosis

Rafael Molina, Xavier Filella, Josep M. Aug eacute et al. · Tumor Biology · 2003 · 275 citations

Medicine, Oncology, Pathology +17

Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

Suresh S. Ramalingam, Fiona Blackhall, Maciej Krzakowski et al. · Journal of Clinical Oncology · 2012 · 266 citations · Full text

Medicine, Oncology, Pharmacology +17